An observational study published in the Journal of Heart and Lung Transplantation in April revealed that Actelion’s oral Uptravi (selexipag) is safe and well-tolerated in children with pulmonary arterial hypertension when administered as an add-on treatment. Selexipag is currently the only prostacyclin receptor agonist approved to target the prostacyclin pathway in adults with pulmonary arterial hypertension.

According to GlobalData, youths under age 18 years had a higher number of adjusted incident cases of pulmonary arterial hypertension in the six major markets in 2019 compared to the 18–19 years old age group. Read more here.